Key result
Urine DOAC dipstick identifies clinically relevant anticoagulation with 100% sensitivity using automated readout.
Why the study?
Rapid assessment of direct oral anticoagulant activity is essential in acute ischemic stroke to guide intravenous thrombolysis decisions, but laboratory assays have limited availability and slow turnaround.
Does urine-based point-of-care DOAC dipstick testing accurately detect clinically relevant DOAC activity compared to plasma assays in acute ischemic stroke patients?
Observational (n=101)
Blinded
No
Does urine-based point-of-care DOAC dipstick testing accurately detect clinically relevant DOAC activity compared to plasma assays in acute ischemic stroke patients?
Answers are grounded in this paper and cite their sources.
Urine-based point-of-care DOAC dipstick testing provides a rapid and highly sensitive method for detecting clinically relevant DOAC activity in acute ischemic stroke patients, potentially accelerating thrombolysis decision-making.
Background: Rapid assessment of direct oral anticoagulant (DOAC) activity is essential in acute ischemic stroke (AIS), particularly because intravenous thrombolysis (IVT) may be considered at anti-Xa levels ≤ 100 ng/mL. Laboratory drug-specific assays; however, are often limited by availability and turnaround time. A urine-based point-of-care (POC) test may provide a rapid alternative. Objectives: To determine the diagnostic accuracy of a urine-based POC dipstick for detecting clinically relevant DOAC activity at (1) the established screening threshold (≥30 ng/mL) and (2) the IVT-relevant threshold (≥100 ng/mL), using calibrated plasma DOAC levels as a reference standard. Methods: In this prospective diagnostic accuracy study (UPTURN trial), consecutive AIS patients underwent urine-based POC testing. Dipstick results, recorded as visual and automatic readouts, were analyzed against plasma DOAC activity. Relevant anticoagulant activity was defined as anti-Xa ≥30 ng/mL; the IVT eligibility threshold was defined as anti-Xa <100 ng/mL. Factor Xa inhibitors were quantified using drug-specific chromogenic anti-Xa assays; dabigatran activity was measured using Biophen DTI. Diagnostic accuracy metrics were calculated with exact 95% CIs. Time-to-result was compared between POC testing and plasma assays. Results: Among 101 AIS patients (55 with DOAC intake), the urine-based dipstick test reliably identified relevant anticoagulatory activity (anti-Xa ≥30 ng/mL) with a sensitivity of 100% and specificity of 96.3% (automated readout). Visual interpretation yielded similar accuracy. For higher anti-Xa levels (≥100 ng/mL), sensitivity remained 100%, though specificity decreased (74.4%). A double-positive visual result increased specificity to 92.8% at 84.4% sensitivity. Median time to result was 19 minutes for urine testing versus 144 minutes for blood-based assays. Test performance was consistent across DOAC agents, dosages, and intake timing. Visual grading enabled semiquantitative discrimination of DOAC levels. Conclusion: Urine-based DOAC dipstick testing is a rapid, accurate, and reliable method for detecting anticoagulatory activity in AIS patients, providing a valuable tool to guide acute therapeutic decisions. Future studies are warranted to validate its clinical impact and broader applicability, especially in the emergency setting.
No takes yet. Share an insight, caveat, or question.
Gerner et al. (2025) conducted an observational in Acute ischemic stroke (n=101). Urine-based point-of-care DOAC dipstick vs. Calibrated plasma DOAC levels was evaluated on Sensitivity of the urine-based dipstick test for detecting specific DOAC levels ≥ 30 ng/mL (Sensitivity 100%, Specificity 96.3%, 95% CI 92.4%-100%). The urine-based DOAC dipstick reliably identified relevant anticoagulatory activity with a sensitivity of 100% and specificity of 96.3% using an automated readout.
Synapse has enriched 10 related papers. Consider them for comparative context: